NCT07288073 2026-02-13TIL Therapy in cSCC and MCCDana-Farber Cancer InstitutePhase 2 Recruiting14 enrolled
NCT02621021 2025-11-21A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabNational Institutes of Health Clinical Center (CC)Phase 2 Recruiting170 enrolled